Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › Amycretin

Amycretin

GLP-1 + amylin (unimolecular) · s.c. / oral · Novo Nordisk

Data cut 12 November 2026 · page built 16 November 2026 · 6 trial arms · 3 trials with results · 19 registered trials · see on the pipeline board

Summary

Also known as
zenagamtide
Mechanism
GLP-1 + amylin (unimolecular)
Route
s.c. / oral
Company
Novo Nordisk
Highest development stage
phase 3
Status (as of data cut)
Phase 3 (AMAZE) started verify
Next milestone
Phase 3 of the oral form

Sources for the status

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity2 phase 3 ongoingPhase 3 (AMAZE) ongoing
T2D2 phase 3 ongoingPhase 2 positive (Lancet 2026); phase 3 ongoingPhase 2 s.c. in T2D
CV outcomes2 phase 3 ongoingPhase 3 ongoing
CKD0 no data
HFpEF0 no data
MASH0 no data
Sleep apnoea0 no data
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
Amycretin oral phase 1oral amycretin 50 mgobesity12144——−10.4 % vs −1.2 %
estimand not specified
−0.2 vs +0.0——31.0 vs 8.038.0 vs 0.00.0 vs 0.0—verified
Amycretin s.c. phase 1b/2aamycretin 60 mgobesity36125−24.3 % vs −1.1 %
Δ −23.2 pp
—−0.6 vs −0.1——82.0 vs 60.047.0 vs 60.00.0 vs 0.0—verified
Amycretin s.c. phase 1b/2aamycretin 20 mgobesity36125−22.0 % vs +2.0 %
Δ −24.0 pp
—−0.3 vs −0.1——79.0 vs 40.053.0 vs 20.03.0 vs 0.0—verified
Zenagamtide s.c. phase 2 (T2D)zenagamtide 10 mg weeklyt2d3638−12.9 % vs −2.1 %
Δ −10.8 pp
—−1.4 vs −0.121.0 vs 6.0—26.0 vs 14.011.0 vs 6.013.0 vs 8.0−9.4 vs −3.5verified
Zenagamtide s.c. phase 2 (T2D)zenagamtide 20 mg weeklyt2d3638−13.1 % vs −2.1 %
Δ −11.0 pp
—−1.6 vs −0.134.0 vs 6.045.0 vs 14.050.0 vs 14.024.0 vs 6.08.0 vs 8.0−7.2 vs −3.5verified
Zenagamtide s.c. phase 2 (T2D)zenagamtide 40 mg weeklyt2d3638−14.6 % vs −2.1 %
Δ −12.5 pp
—−1.7 vs −0.134.0 vs 6.045.0 vs 14.037.0 vs 14.029.0 vs 6.03.0 vs 8.0−10.6 vs −3.5verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (37)
  • amycretin 60 mg · nausea · Table 2 (Parts B–E; columns: 60 mg [B], pbo B, 20 mg [C], pb
    Nausea 14 (82%), 17 3 (60%), 3 27 (79%), 36 2 (40%), 2 12 (75%), 12 1 (25%), 1 8 (50%), 8 2 (50%), 2
  • amycretin 60 mg · vomiting · Table 2 (Parts B–E; columns: 60 mg [B], pbo B, 20 mg [C], pb
    Vomiting 8 (47%), 15 3 (60%), 3 18 (53%), 20 1 (20%), 1 4 (25%), 5 0 5 (31%), 5 1 (25%), 1
  • amycretin 60 mg · sae · Table 2 (Parts B–E; columns: 60 mg [B], pbo B, 20 mg [C], pb
    Yes 0 0 1 (3%), 1 0 0 0 0 0
  • amycretin 60 mg · hba1c · Table 3, Glycated haemoglobin rows
    Estimated change from baseline to EOT –0·6% (0·1) –0·1% (0·2)
  • amycretin 20 mg · weight_eff · Table 3
    Estimated change from baseline to EOT –24·3% (1·9) –1·1% (3·0) –22·0% (1·0) 1·9% (2·5) –16·2% (1·1) 2·3% (1·8) –9·7% (1·3) 2·0% (2·4)
  • amycretin 20 mg · nausea · Table 2 (Parts B–E; columns: 60 mg [B], pbo B, 20 mg [C], pb
    Nausea 14 (82%), 17 3 (60%), 3 27 (79%), 36 2 (40%), 2 12 (75%), 12 1 (25%), 1 8 (50%), 8 2 (50%), 2
  • amycretin 20 mg · vomiting · Table 2 (Parts B–E; columns: 60 mg [B], pbo B, 20 mg [C], pb
    Vomiting 8 (47%), 15 3 (60%), 3 18 (53%), 20 1 (20%), 1 4 (25%), 5 0 5 (31%), 5 1 (25%), 1
  • amycretin 20 mg · sae · Table 2
    Yes 0 0 1 (3%), 1 0 0 0 0 0
  • amycretin 20 mg · hba1c · Table 3
    Estimated change from baseline to EOT –0·6% (0·1) –0·1% (0·2) –0·3% (0·1) –0·1% (0·1) –0·2% (0·1) 0·1% (0·1) –0·2% (0·1) –0·1% (0·1)
  • oral amycretin 50 mg · nausea · Table 2 (part C/D TEAEs): columns 50 mg (n=16), 2x50 mg (16)
    Nausea 5 (31%) 6 12 (75%) 14 15 (94%) 18 1 (8%)
  • oral amycretin 50 mg · sae · Table 2 (part C/D TEAEs): columns 50 mg (n=16), 2x50 mg (16)
    Serious adverse event Yes 0 0 0 0 1 (6%) 1 0 0
  • oral amycretin 50 mg · vomiting · Table 2 (part C/D TEAEs): columns 50 mg (n=16), 2x50 mg (16)
    Vomiting 6 (38%) 7 9 (56%) 11 10 (63%) 11 0 0
  • oral amycretin 50 mg · hba1c · Table 3
    HbA1c, % Screening, mean (SD) 5·2 (0·4) 5·2 (0·3) 5·4 (0·4) 5·3 (0·4) Day 85, mean (SD) 5·0 (0·3) 5·0 (0·2) 5·1 (0·2) 5·3 (0·3) Change from day 1 to day 85, mean (SD) –0·2 (0·2) –0·3 (0·3) –0·3 (0·2) 0·0 (0·2) ETD (95% C
  • oral amycretin 50 mg · weight_unsp · Table 3 (exploratory PD endpoints part C/D), column 1 = Amyc
    Amycretin 50 mg (n=16) Amycretin 2 × 50 mg (n=16) Amycretin 2 × 25 mg (n=16) Placebo* (n=12) Bodyweight, % Change from day 1 to day 85, mean (SD) –10·4 (4·6) –13·1 (4·8) –12·2 (4·5) –1·2 (2·4) Minimum change –2·2 –6·2 –4
  • zenagamtide 10 mg weekly · weight_eff · Table 2, Bodyweight change, % row
    −4·3 −7·6 −8·2 −12·9 −13·1 −14·6 −2·1
  • zenagamtide 10 mg weekly · ae_dc · Table 3
    Action taken: trial treatment discontinued 3 (8%) 1 (3%) 6 (16%) 8 (21%) 13 (34%) 13 (34%) 2 (6%)
  • zenagamtide 10 mg weekly · nausea · Table 3
    Nausea 4 (11%) 6 (17%) 14 (38%) 10 (26%) 19 (50%) 14 (37%) 5 (14%)
  • zenagamtide 10 mg weekly · vomiting · Table 3
    Vomiting 1 (3%) 1 (3%) 6 (16%) 4 (11%) 9 (24%) 11 (29%) 2 (6%)
  • zenagamtide 10 mg weekly · sae · Results, adverse events paragraph; Table 3
    five (13%) in the 10 mg group
  • zenagamtide 10 mg weekly · hba1c · Table 2
    Change from baseline at week 36 −0·9 −1·3 −1·0 −1·4 −1·6 −1·7 −0·1
  • zenagamtide 10 mg weekly · sbp · Table 2, SBP row
    Change from baseline at week 36 −5·8 −3·4 −7·7 −9·4 −7·2 −10·6 −3·5
  • zenagamtide 20 mg weekly · weight_eff · Table 2, Bodyweight change, % row
    −4·3 −7·6 −8·2 −12·9 −13·1 −14·6 −2·1
  • zenagamtide 20 mg weekly · ae_dc · Table 3
    Action taken: trial treatment discontinued 3 (8%) 1 (3%) 6 (16%) 8 (21%) 13 (34%) 13 (34%) 2 (6%)
  • zenagamtide 20 mg weekly · disc_any · Results, paragraph 2
    17 (45%) of 38 participants in the zenagamtide 20 mg and 40 mg groups
  • zenagamtide 20 mg weekly · nausea · Table 3
    Nausea 4 (11%) 6 (17%) 14 (38%) 10 (26%) 19 (50%) 14 (37%) 5 (14%)
  • zenagamtide 20 mg weekly · vomiting · Table 3
    Vomiting 1 (3%) 1 (3%) 6 (16%) 4 (11%) 9 (24%) 11 (29%) 2 (6%)
  • zenagamtide 20 mg weekly · sae · Results, adverse events paragraph; Table 3
    three (8%) in the 20 mg group
  • zenagamtide 20 mg weekly · hba1c · Table 2
    Change from baseline at week 36 −0·9 −1·3 −1·0 −1·4 −1·6 −1·7 −0·1
  • zenagamtide 20 mg weekly · sbp · Table 2, SBP row
    Change from baseline at week 36 −5·8 −3·4 −7·7 −9·4 −7·2 −10·6 −3·5
  • zenagamtide 40 mg weekly · weight_eff · Results, paragraph 7; Table 2
    to −14·6% with zenagamtide 40 mg (−12·5% [−16·79 to −8·21]; p<0·0001), compared with −2·1% with placebo
  • zenagamtide 40 mg weekly · ae_dc · Table 3
    Action taken: trial treatment discontinued 3 (8%) 1 (3%) 6 (16%) 8 (21%) 13 (34%) 13 (34%) 2 (6%)
  • zenagamtide 40 mg weekly · disc_any · Results, paragraph 2
    17 (45%) of 38 participants in the zenagamtide 20 mg and 40 mg groups
  • zenagamtide 40 mg weekly · nausea · Table 3
    Nausea 4 (11%) 6 (17%) 14 (38%) 10 (26%) 19 (50%) 14 (37%) 5 (14%)
  • zenagamtide 40 mg weekly · vomiting · Results, adverse events paragraph; Table 3
    vomiting in one (3%) of 38 participants in the 0·4 mg group and 11 (29%) of 38 participants in the 40 mg group
  • zenagamtide 40 mg weekly · sae · Results, adverse events paragraph; Table 3
    one (3%) in the 40 mg group
  • zenagamtide 40 mg weekly · hba1c · Results, paragraph 3; Table 2
    to −1·7% with zenagamtide 40 mg (−1·56% [−2·05 to −1·07]; p<0·0001; table 2)
  • zenagamtide 40 mg weekly · sbp · Table 2, SBP row
    Change from baseline at week 36 −5·8 −3·4 −7·7 −9·4 −7·2 −10·6 −3·5

Registered trials (19)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
AMAZE 13
AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight
ObesityPhase 3not yet recruiting2027-01 → 2029-01400not yet recruitingNCT07668401
AMBITION 1
A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
T2DPhase 3not yet recruiting2026-11 → 2028-06200not yet recruitingNCT07931495
AMBITION 2
A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both
CKDPhase 3not yet recruiting2026-11 → 2028-07450not yet recruitingNCT07931547
AMBITION 3
AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
T2DPhase 3not yet recruiting2026-11 → 2028-071200not yet recruitingNCT07931573
AMBITION4
A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both
T2DPhase 3not yet recruiting2026-11 → 2028-071060not yet recruitingNCT07931599
AMBIENCE
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
CV outcomesPhase 3not yet recruiting2026-10 → 2030-098500not yet recruitingNCT07861100
AMAZE 7
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
ObesityPhase 3recruiting2026-09 → 2028-10650recruitingNCT07668414
AMAZE 10
AMAZE 10: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People in Japan With Excess Body Weight Lose Weight
ObesityPhase 3recruiting2026-09 → 2029-02400recruitingNCT07822061
AMAZE 9
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
ObesityPhase 3recruiting2026-08 → 2028-06950recruitingNCT07720271
AMBITION 7
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
T2DPhase 3recruiting2026-08 → 2028-071778recruitingNCT07797335
AMAZE 8
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
ObesityPhase 3active not recruiting2026-05 → 2028-12985active not recruitingNCT07400107
HF-POLARIS
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
CV outcomesPhase 3recruiting2026-05 → 2029-075610recruitingNCT07567001
AMAZE 3
AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
Sleep apnoeaPhase 3recruiting2026-05 → 2028-07300recruitingNCT07571005
AMAZE 4
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
Sleep apnoeaPhase 3recruiting2026-05 → 2028-06300recruitingNCT07571109
AMAZE 5
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
Knee OAPhase 3recruiting2026-04 → 2028-08400recruitingNCT07481630
AMAZE 12
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
ObesityPhase 3active not recruiting2026-04 → 2028-06606active not recruitingNCT07503210
AMAZE 6
AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
Knee OAPhase 3recruiting2026-04 → 2028-08400recruitingNCT07509307
AMAZE 2
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
ObesityPhase 3active not recruiting2026-04 → 2028-08638active not recruitingNCT07533175
AMAZE 1
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
ObesityPhase 3recruiting2026-02 → 2029-061150recruitingNCT07339423

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Amycretin. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/amycretin/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.